Company working with a leading global law firm to support worldwide licensing and/or co-development initiatives intended to help fund U.S. regulatory development and create potential pathways for international commercialization
SAN DIEGO, California, 24th September, 2026 – AscentX Medical, Inc. (“AscentX” or the “Company”) today announced that the Company has eliminated $5.05 million of secured long-term debt, marking an important financial milestone, as it advances its US and global regulatory and commercialization strategy for its medical technology portfolio.
With the legacy debt eliminated, AscentX enters its next stage of development with a simplified capital structure and increased financial flexibility. The Company is now able to direct future capital toward advancing its technologies, regulatory programs and commercialization initiatives rather than toward expensive and stifling legacy debt service.
AscentX is working with a leading, global, life sciences law firm to assist the Company in developing and executing worldwide licensing and co-development strategies for its medical technology portfolio. These initiatives are intended to establish strategic relationships with qualified partners across international markets while generating capital and other resources to help fund the Company’s planned pursuit of U.S. Food and Drug Administration (FDA) clearance or approval, as applicable. AscentX is also considering offering a special preferred series to further assist in the execution of this strategy.
“Restructuring the balance sheet is an important milestone for AscentX and represents a significant step in positioning the Company for its next phase of development,” said Larry J. Braga, Acting Chief Executive Officer and Vice President, Manufacturing Operations. “Our strategy is to combine disciplined U.S. regulatory development with international licensing relationships that may provide both capital and potential pathways to commercialization in markets throughout the world.”
Global Licensing and Co-Development Strategies
AscentX’s global licensing and co-development strategies are expected to include opportunities involving its G-125, U-125 and F-40 technologies, targeting gastroesophageal reflux disease (GERD), stress urinary incontinence (SUI), and aesthetic medicine, respectively. The Company’s strategy targets strategic capital from licensing and co-development, for the continued advancement of its technologies and U.S. FDA clearance or approval, as applicable, potentially reducing the Company’s dependence on traditional equity financing.
Under these arrangements, global partners providing licensing and/or co-development capital may receive defined territorial rights to pursue local regulatory authorization and commercialization. These rights may be structured separately by product, indication, country or geographic region, allowing AscentX to develop a network of strategic partners.
Depending upon the applicable product and territory, potential licensing arrangements may include:
- Upfront licensing payments;
- Development and regulatory milestone payments;
- Territorial commercialization rights;
- Product sales and distribution rights;
- Royalties on future commercial sales; and
- Other strategic or commercial payments.
AscentX intends to retain appropriate control over its intellectual property, technology, manufacturing standards, brand, and regulatory documentation while providing licensees and co-developers with the contractual rights and the relevant technical, clinical, manufacturing, and regulatory information support necessary to pursue regulatory authorization and commercialization within their licensed territories.
U.S. Regulatory Pathway
AscentX plans to pursue U.S. FDA clearance or approval, as applicable, for programs within its medical technology portfolio, including solutions for gastroesophageal reflux disease (GERD), stress urinary incontinence (SUI), and aesthetic medicine. In parallel with its U.S. regulatory strategy, the Company intends to pursue licensing and/or co-development agreements with qualified strategic partners globally. The Company believes this approach has the potential to create a coordinated global development strategy in which global capital can help support AscentX’s U.S. regulatory program while global partners simultaneously pursue regulatory and commercialization pathways in territories outside the U.S.
About AscentX Medical, Inc.
AscentX Medical, Inc. is a San Diego-based medical technology company focused on developing innovative therapeutic and aesthetic technologies. The Company’s portfolio includes G-125, U-125 and F-40 technologies, with programs being developed or evaluated for applications including gastroesophageal reflux disease (GERD), stress urinary incontinence (SUI), and aesthetic medicine.
Forward-Looking Statements
This press release contains forward-looking statements, including statements concerning AscentX Medical’s product-development programs, plans to pursue FDA clearance or approval, as applicable, international regulatory strategies, worldwide licensing and co-development initiatives, potential licensing and co-development payments, finance strategy and commercialization plans. Regulatory requirements vary by jurisdiction, and regulatory authorization in one jurisdiction does not guarantee approval or authorization in another. There can be no assurance that the Company will obtain FDA or other regulatory clearances, approvals or authorizations, successfully complete licensing and co-development initiatives, receive anticipated licensing and/or co-development payments or successfully commercialize its technologies. Actual results may differ materially from those expressed or implied by these statements because the Company may not realize its expectations, and its beliefs may not prove correct. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as the Company’s current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance, or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Media and Investor Inquiries
Larry J. Braga
Chief Executive Officer
AscentX Medical, Inc.
6190 Cornerstone Ct E, Suite 230
San Diego, CA 92121